CN114585738A - 用于治疗血小板减少症的核酸分子及其应用 - Google Patents

用于治疗血小板减少症的核酸分子及其应用 Download PDF

Info

Publication number
CN114585738A
CN114585738A CN202080065027.2A CN202080065027A CN114585738A CN 114585738 A CN114585738 A CN 114585738A CN 202080065027 A CN202080065027 A CN 202080065027A CN 114585738 A CN114585738 A CN 114585738A
Authority
CN
China
Prior art keywords
nucleic acid
thpo
small activating
acid molecule
promoter region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080065027.2A
Other languages
English (en)
Chinese (zh)
Inventor
李龙承
姜武林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sino American Ruikang Nucleic Acid Technology Nantong Research Institute Co ltd
Original Assignee
Sino American Ruikang Nucleic Acid Technology Nantong Research Institute Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sino American Ruikang Nucleic Acid Technology Nantong Research Institute Co ltd filed Critical Sino American Ruikang Nucleic Acid Technology Nantong Research Institute Co ltd
Publication of CN114585738A publication Critical patent/CN114585738A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CN202080065027.2A 2019-09-20 2020-09-18 用于治疗血小板减少症的核酸分子及其应用 Pending CN114585738A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019108915088 2019-09-20
CN201910891508 2019-09-20
PCT/CN2020/116227 WO2021052470A1 (zh) 2019-09-20 2020-09-18 用于治疗血小板减少症的核酸分子及其应用

Publications (1)

Publication Number Publication Date
CN114585738A true CN114585738A (zh) 2022-06-03

Family

ID=74883124

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080065027.2A Pending CN114585738A (zh) 2019-09-20 2020-09-18 用于治疗血小板减少症的核酸分子及其应用

Country Status (12)

Country Link
US (1) US20230212565A1 (https=)
EP (1) EP4036232A4 (https=)
JP (1) JP2022552940A (https=)
KR (1) KR20220070206A (https=)
CN (1) CN114585738A (https=)
AU (1) AU2020349991A1 (https=)
BR (1) BR112022005028A2 (https=)
CA (1) CA3148158A1 (https=)
CO (1) CO2022004857A2 (https=)
PE (1) PE20220604A1 (https=)
TW (1) TW202126808A (https=)
WO (1) WO2021052470A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111849968A (zh) 2019-04-30 2020-10-30 中美瑞康核酸技术(南通)研究院有限公司 寡核苷酸分子及其在急性间歇性卟啉症治疗中的应用
WO2024216109A1 (en) * 2023-04-12 2024-10-17 Alnylam Pharmaceuticals, Inc. Formulations for oligonucleotide delivery

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996029411A1 (en) * 1995-03-17 1996-09-26 Transkaryotic Therapies, Inc. Protein production and delivery
CN1141061A (zh) * 1994-01-03 1997-01-22 基因技术股份有限公司 血小板生成素
WO2010144740A1 (en) * 2009-06-10 2010-12-16 Alnylam Pharmaceuticals, Inc. Improved lipid formulation
CN103842508A (zh) * 2011-06-21 2014-06-04 米纳治疗有限公司 白蛋白产生和细胞增殖
CN106032532A (zh) * 2015-03-17 2016-10-19 中国医学科学院北京协和医院 一种小激活rna及其制备方法和应用
CN106480028A (zh) * 2016-10-12 2017-03-08 上海市第七人民医院 TPO基因的saRNA分子及其应用
WO2017106283A1 (en) * 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Compositions and methods for treatment of liver diseases
US20180305689A1 (en) * 2015-04-22 2018-10-25 Mina Therapeutics Limited Sarna compositions and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1871426B1 (en) * 2005-04-15 2017-06-07 The Regents of The University of California Small activating rna molecules and their use
WO2007086990A2 (en) * 2005-11-17 2007-08-02 Board Of Regents, The University Of Texas System Modulation of gene expression by oligomers targeted to chromosomal dna
GB201010557D0 (en) * 2010-06-23 2010-08-11 Mina Therapeutics Ltd RNA molecules and uses thereof
KR102599712B1 (ko) * 2015-04-22 2023-11-09 미나 테라퓨틱스 리미티드 C/EBP 알파 saRNA 조성물 및 사용 방법

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1141061A (zh) * 1994-01-03 1997-01-22 基因技术股份有限公司 血小板生成素
WO1996029411A1 (en) * 1995-03-17 1996-09-26 Transkaryotic Therapies, Inc. Protein production and delivery
WO2010144740A1 (en) * 2009-06-10 2010-12-16 Alnylam Pharmaceuticals, Inc. Improved lipid formulation
CN103842508A (zh) * 2011-06-21 2014-06-04 米纳治疗有限公司 白蛋白产生和细胞增殖
CN106032532A (zh) * 2015-03-17 2016-10-19 中国医学科学院北京协和医院 一种小激活rna及其制备方法和应用
US20180305689A1 (en) * 2015-04-22 2018-10-25 Mina Therapeutics Limited Sarna compositions and methods of use
WO2017106283A1 (en) * 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Compositions and methods for treatment of liver diseases
CN106480028A (zh) * 2016-10-12 2017-03-08 上海市第七人民医院 TPO基因的saRNA分子及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DORDELMANN C等: "NG_012136.1", 《GENBANK》, 4 August 2019 (2019-08-04), pages 1 - 10 *

Also Published As

Publication number Publication date
KR20220070206A (ko) 2022-05-30
BR112022005028A2 (pt) 2022-07-05
AU2020349991A1 (en) 2022-04-07
WO2021052470A1 (zh) 2021-03-25
EP4036232A1 (en) 2022-08-03
TW202126808A (zh) 2021-07-16
EP4036232A4 (en) 2023-01-11
CO2022004857A2 (es) 2022-07-08
CA3148158A1 (en) 2021-03-25
PE20220604A1 (es) 2022-04-25
US20230212565A1 (en) 2023-07-06
JP2022552940A (ja) 2022-12-21

Similar Documents

Publication Publication Date Title
Bin Moon et al. Highly efficient genome editing by CRISPR-Cpf1 using CRISPR RNA with a uridinylate-rich 3′-overhang
WO2020205605A3 (en) OLIGONUCLEOTIDE-BASED MODULATION OF C9orf72
MX2023008478A (es) Nucleótidos modificados con 5´-ciclo-fosfonato.
JP2018531037A5 (https=)
WO2017053431A3 (en) Allele selective gene editing and uses thereof
FI3445388T3 (fi) Materiaaleja ja menetelmiä hemoglobinopatioiden hoitamiseksi
WO2023041508A3 (en) Treatment of cardiovascular disease
FI3597749T3 (fi) Menetelmiä ja koostumuksia rna-ohjattua kohde-dna-modifikaatiota varten ja rna-ohjattua transkription modulaatiota varten
JP2016521995A5 (https=)
EA201892366A1 (ru) Антисмысловые олигомеры и способы их применения для лечения заболеваний, связанных с геном кислой альфа-глюкозидазы
FI3604532T3 (fi) Uusia crispr-entsyymejä ja järjestelmiä
RU2016101178A (ru) Доставка, конструирование и оптимизация систем, способы и композиции для целенаправленного воздействия и моделирования заболеваний и нарушений постмитотических клеток
WO2010141511A3 (en) Polynucleotides for multivalent rna interference, compositions and methods of use thereof
JP2016537990A5 (https=)
CN114585738A (zh) 用于治疗血小板减少症的核酸分子及其应用
EA201070108A1 (ru) Cd44 сплайс-варианты в нейродегенеративных заболеваниях
CN110678549B (zh) 一种激活p21基因表达的方法
Surgucheva et al. Matrix metalloproteinase 9 expression: new regulatory elements
Rezzoug et al. Discovery of a family of genomic sequences which interact specifically with the c-MYC promoter to regulate c-MYC expression
JP2018520150A5 (https=)
Garafutdinov et al. New method for microRNA detection based on multimerization
EP2255002B1 (en) Method to inhibit ribonuclease dicer, ribonuclease dicer inhibitor, and use of rna aptamers as ribonuclease dicer inhibitors
ATE550436T1 (de) Sensibilisierung von krebszellen für eine therapie unter verwendung von sina-zielgenen aus den chromosomenregionen 1p und 19q
CN103993005B (zh) 巯基化单链dna在聚合酶链式反应中的应用
MX2021013361A (es) Molecula oligomerica de acido nucleico y uso de esta en el tratamiento de la porfiria aguda intermitente.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40073799

Country of ref document: HK